THE NONLIPID AND ANTI-INFLAMMATORY EFFECTS OF ROSUVASTATIN IN CARDIAC RECIPIENTS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The non-lipid effects of rosuvastatin (Mertinil) were studied in patients after heart transplantation, which were evaluated from the time course of changes in the levels of C-reactive protein (CRP) and biomarkers for a risk of graft vasculopathy. In cardiac recipients, rosuvastatin (Mertinil) was found to produce both lipid-lowering and anti-inflammatory effects (a reduction in CRP levels); its intake promotes a decrease in the biomarkers (PAPP-A and sCD40L) of a risk for cardiac graft vasculopathy.

Full Text

Restricted Access

References

  1. Болезнь коронарных артерий пересаженного сердца. Под ред. В.И. Шумакова / М.: ООО «Медицинское информационное агентство». - 208; 160 с.
  2. Шевченко А.О., Шевченко О.П. Эффективность и безопасность розувастатина в суточной дозе 5 мг // Врач. - 2011; 9: 30-3.
  3. Abu-Qaoud M.S., Stoletniy L.N., Chen D. et al. Lack of relationship between microvascular and macrovascular disease in heart transplant recipients // Transplantation. - 2012; 94 (9): 965-70.
  4. Aharinejad S., Krenn K., Zuckermann A. et al. Matrix metalloproteinases and their tissue inhibitor in cardiac transplantation // Eur. J. Cardiothorac. Surg. - 2007; 32: 48-51.
  5. Furman C., Copin C., Kandoussi M. et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability // Atherosclerosis. - 2004; 174: 93-8.
  6. Gazi I., Liberopoulos E., Athyros V. et al. Statins and solid organ transplantation // Curr. Pharm. Des. - 2006; 12: 4771-83.
  7. Kobashigawa J., Moriguchi J., Laks H. et al. Ten-year follow- up of a randomized trial of pravastatin in heart transplant patients // J. Heart Lung. Transplant. - 2005; 24: 1736-40.
  8. Kobashigawa J. Statins and cardiac allograft vasculopathy after heart transplantation // Sem. Vasc. Med. - 2004; 4: 401-6.
  9. Mehra M., Raval N. Metaanalysis of statins and survival in de novo cardiac transplantation // Transplant. Proc. - 2004; 36: 1539-41.
  10. Segovia J., Gomez-Bueno M., Alonso-Pulpon L. Treatment of allograft vasculopathy in heart transplantation // Exp. Opin. Pharmacother. - 2006; 7: 2369-83.
  11. Shevchenko O.P., Khalilulin T.A., Shevchenko A.O. et al. Comparision of predictive significance of soluble CD40ligand, pregnancy-associated plasma protein A, and placental growth factor for graft failure development after heart transplantation // J. Heart Lung. Transplant. - 2012; 31 (4S): 172-3.
  12. Stein W., Schrepfwer S., Iton S. et al. Prevention of transplant coronary artery disease by prenylation inhibitors // J. Heart Lung. Transplant. - 2011; 30: 761-9.
  13. Suzuki J., Isobe M., Kawauchi M. et al. Altered expression of matrix metalloproteinases and tissue inhibitors of metal-loproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates // Transplant. Int. - 2000; 13: 106-13.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies